Journal of interferon research最新文献

Interferon-gamma (IFN-gamma) specifically induced the uptake of the unsaturated fatty acid [14C]linoleic acid into membrane phospholipids of the murine macrophage-like P388D cell lineage, but did not alter the incorporation of the saturated fatty acid [14C]stearic acid. Spin label ESR spectroscopy was used to examine any effects of these IFN-gamma-induced changes on membrane fluidity and the results revealed significant increases in plasma membrane fluidity. This alteration in membrane fluidity may have important consequences in the dynamic properties of cellular physiochemical interactions and some of the stimulatory effects of IFN-gamma on macrophages might be attributed to its effects on the plasma membrane composition.

Interferon-gamma (IFN-gamma) has potent antiproliferative effects on the endothelium, although the specific mechanisms responsible for this effect are not clear. We tested the hypothesis that suppression of endothelial cell proliferation by IFN-gamma is mediated by an increase in xanthine oxidase-derived O2-.. Human umbilical vein endothelial cells (HUVEC) were exposed to recombinant human IFN-gamma. We found that [3H]thymidine uptake decreased (p < 0.05) with increasing doses of IFN-gamma. Treatment of HUVEC with the xanthine oxidase inhibitor allopurinol or the O2-. scavenger superoxide dismutase had no effect (p > 0.05) on [3H]thymidine uptake of IFN-gamma-treated cells. In parallel, IFN-gamma decreased (p < 0.05) HUVEC cell counts, while allopurinol again had no effect (p > 0.05) on cell counts of IFN-gamma-treated or control HUVEC. In addition, xanthine oxidase activity of HUVEC did not (p > 0.05) increase following treatment with IFN-gamma. We conclude that IFN-gamma suppresses HUVEC proliferation by a mechanism independent of O2-. production by xanthine oxidase.

Several field isolates, strains, mutants, and revertants of vesicular stomatitis virus (VSV), Indiana (IN) serotype, were studied that differed greatly in their capacity to induce interferon (IFN) in aged chick embryo cells. The predicted M-protein amino acid sequence of a wild-type field isolate that induced > or = 10,000 units/ml IFN in chicken embryo cells was identical to that of a wild-type field isolate that induced < 2 units/ml and of a noninducing wild-type laboratory strain. The 47-base plus-strand leader RNA sequences were the same for five IFN-inducing, and eight noninducing independent isolates of wild-type VSV IN. Our data show that the M-protein and plus-strand leader RNA do not of themselves regulate the induction of IFN in this system. Because the capacity of VSV IN to induce IFN resides in virion-associated elements (Marcus and Sekellick, 1987, J. Interferon Res. 7, 269-284), the differences in IFN yield observed with various isolates must result from changes in other virion components that remain to be determined.

p106 is a human membrane protein of 106 kD previously shown to be inducible by interferon-alpha (IFN-alpha) on Daudi cells. To investigate the role of p106 further, its distribution and inducibility within hematopoietic cells was studied. Multiparameter flow cytometry (FCM) analysis showed that p106 expression was restricted to B cells and monocytes, and in both cell lineages acquired at a late stage of differentiation. Thus, p106 was found on mature B lymphocytes and monocytes in peripheral blood and on a variety of freshly isolated leukemic cells of B and myeloid origin as well as on a variety of cultured B-cell lines. In contrast, no expression was found on T lymphocytes, natural killer (NK) cells or granulocytes. p106 expression could be further induced by IFN-alpha on monocytes and Daudi cells, and this capacity was shown to be selective for IFN-alpha, since no other cytokines tested induced p106. Moreover, IFN-alpha therapy of chronic myeloid leukemia (CML) and hairy cell leukemia (HCL) patients lead to a clearcut induction of p106 on such malignant cells. The distribution of p106 could suggest that it represents an activation antigen. Further studies, including cloning of p106 cDNA, are needed to determine the function of p106.

Some common viruses responsible for respiratory disease have been reported to be poor inducers of interferon (IFN). Therefore, we have studied the induction of IFN in cultures of human leukocytes exposed under standardized conditions to various concentrations of adenovirus type 7A, coronavirus 229E, an influenza type A virus (H3N2), a rhinovirus, and respiratory syncytial virus (RSV). All five viruses induced substantial amounts of IFN at a multiplicity of infection of one infectious unit per cell or less. Leukocyte cultures from 50 healthy children were exposed to a standard concentration of each of the viruses. IFN was induced almost without an exception, but the amounts produced varied extensively according to both the virus and the individual leukocyte donor.

Human papillomaviruses (HPV) are associated with malignant cervical neoplasia. Several HPV-related diseases have been shown to be sensitive to interferon (IFN) treatment. HeLa cells contain and express the HPV type 18 genome and were used as a model for the evaluation of the viral expression regulation and the effect on the malignant phenotype during IFN treatment. Cells were treated continuously with 200 IU/ml IFN-alpha 2b or natural leukocyte INF-alpha for six passages (42 days). Some IFN-induced changes were observed: decrease of HPV-18 mRNA expression, changes of cell morphology, and reduction of clonogenicity in soft agar. Tumorigenicity in nude mice was not modified. Other targets of the IFN system were analyzed, and an increase of the 2',5'-oligoadenylate synthetase mRNA level and a down-regulation of type I IFN receptor were found. These results demonstrate that long-term IFN-alpha treatment induces a partial phenotypic reversion of HeLa cells to a more differentiated stage were down-regulation of HPV-18 expression could play a central role. It therefore confirms that the IFN-alpha treatment may be therapeutically useful in cervix cancer produced by HPV-18.

The D variant of encephalomyocarditis virus (EMCV-D) produces a disease syndrome that mimics insulin-dependent diabetes mellitus (IDDM) in certain mouse strains. Benign EMCV-B interferes with the ability of EMCV-D to produce IDDM. Because EMCV-B induces the production of relatively large amounts of interferon (IFN), it has been hypothesized that the interference by EMCV-B with the pathogenesis of EMCV-D is due to IFN. However, we have previously reported that in outbred ICR Swiss and inbred BALB/cByJ mice, interference by EMCV-B with the development of IDDM in response to infection with EMCV-D does not appear to involve IFN. We have isolated a subvariant of EMCV-B (EMCV-B1) which, preliminary experiments indicate, does not induce the production of detectable levels of IFN in cell culture. Studies were initiated using this subvariant to determine more conclusively if IFN is involved in interference by EMCV-B with the pathogenesis of EMCV-D. The data in the present study show that EMCV-B1 does not induce the production of detectable levels of IFN either in cell culture or in mice, but retains other reported characteristics of the parent EMCV-B, including the ability to interfere with the production of IDDM by EMCV-D in ICR Swiss male mice. These observations strengthen the hypothesis that protection of pancreatic beta cells in ICR Swiss mice by EMCV-B occurs by a mechanism other than IFN.

The autophosphorylation of interferon (IFN)-induced double-stranded RNA-dependent p68 protein kinase (PKR) and phosphorylation of the alpha-subunit of the translation initiation factor eIF-2 were inhibited by 10 mM 2-aminopurine in vitro. High concentrations of ATP overcame the inhibition. Kinetic studies indicated that 2-aminopurine is a competitive inhibitor with respect to ATP, suggesting that these two molecules bind the same site on the kinase. Treatment of HeLa cells with poly(I):poly(C) stimulated PKR autophosphorylation in vivo. The stimulated activity was inhibited by 10 mM 2-aminopurine to approximately the same extent as the in vitro inhibition.

A pilot study was undertaken to test the safety and establish the side effect profile of recombinant human interferon-beta 1b (Betaseron, Berlex Laboratories, Richmond, CA), in patients with relapsing-remitting multiple sclerosis (RRMS). During the initial dose finding period (24 weeks), five groups of 6 patients each were treated by subcutaneous injection three times each week with either 0.8, 4, 8, or 16 million units (mU) of Betaseron or placebo (WHO Standard). Although some side effects were noted in all groups, a dose-related trend in reduction of exacerbation frequency and side-effect profile was noted. Patients given 16 mU had no exacerbations during the initial dosing period, but associated side effects led to dose reduction or dropout. An 8 mU dose was selected for further study after 24 weeks, and continuous dosing at 8 mU in 15 patients has now exceeded 6 years. Side effects abated over time. Neutralizing antibody developed in most patients, but titers were variable, fluctuated independently of clinical course, and tended to fall with prolonged treatment. A dose-dependent rise in neopterin levels was observed during the initial dosing period. This pilot study has demonstrated responsiveness to Betaseron, shown a stable safety profile over time, and established guidelines for a dosing regimen to evaluate and optimize further the efficacy of Betaseron in RRMS.

The biological activity of a novel recombinant interferon, r-metIFN-con1, which represents a consensus sequence of the most commonly appearing amino acids at each locus of 14 naturally occurring IFN-alpha s, was assessed and compared to that of IFN-alpha 2a. The increase in cellular mRNA levels for three IFN-inducible genes served as a quantitative measure of the effectiveness of the stimulation by each of the IFNs. Three cell lines were treated with equimolar amounts of two IFNs encompassing a 5 log range and mRNA was extracted at five different times after treatment. In all cases, r-metIFN-con1 produced mRNA increases at lower concentrations than IFN-alpha 2a. HLA-DR alpha mRNA, which is not affected by IFN-alpha in ME180 or Daudi cells, was also not affected by r-metIFN-con1. However, in Eskol cells, both IFNs effected an increase in HLA-DR alpha mRNA to similar levels. The r-metIFN-con1 was effective at approximately 10-fold lower molar concentrations. At effective concentrations (10-fold lower molar dose of r-metIFN-con1), both IFNs produced similar kinetics of accumulation of all three mRNAs tested. r-metIFN-con1 is therefore more effective than IFN-alpha 2a at the level of mRNA regulation as well as the antiviral and antiproliferative activities that have been reported previously.